Andrew Tsai
Stock Analyst at Jefferies
(2.94)
# 1,441
Out of 5,131 analysts
29
Total ratings
52.17%
Success rate
0.24%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.66 | +36.34% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $34.30 | -12.54% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $288.45 | +56.01% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $18.02 | +77.58% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $16.37 | +52.72% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.50 | -6.98% | 1 | Oct 22, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $187.62 | +1.27% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $23.83 | +46.87% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $32.85 | -8.68% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $77.25 | -9.39% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.73 | -32.98% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $169.38 | +18.08% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $17.04 | +58.45% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.31 | +201.62% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $28.96 | +20.86% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.17 | +156.41% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $6.75 | +344.44% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.75 | +620.00% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $42.15 | -45.43% | 1 | Jun 1, 2020 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.66
Upside: +36.34%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $34.30
Upside: -12.54%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $288.45
Upside: +56.01%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $18.02
Upside: +77.58%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $16.37
Upside: +52.72%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.50
Upside: -6.98%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $187.62
Upside: +1.27%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $23.83
Upside: +46.87%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $32.85
Upside: -8.68%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $77.25
Upside: -9.39%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.73
Upside: -32.98%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $169.38
Upside: +18.08%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $17.04
Upside: +58.45%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.31
Upside: +201.62%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $28.96
Upside: +20.86%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.17
Upside: +156.41%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $6.75
Upside: +344.44%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.75
Upside: +620.00%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $42.15
Upside: -45.43%